DiscoverHealthTech Deep DiveOPERE, operator of medical communication SaaS “Pokesapo,” raises 400 million yen in pre-Series A funding. How does it differ from patient explanation support services such as Contrea and MediOS?
OPERE, operator of medical communication SaaS “Pokesapo,” raises 400 million yen in pre-Series A funding. How does it differ from patient explanation support services such as Contrea and MediOS?

OPERE, operator of medical communication SaaS “Pokesapo,” raises 400 million yen in pre-Series A funding. How does it differ from patient explanation support services such as Contrea and MediOS?

Update: 2025-07-07
Share

Description

This collection of articles explores recent innovations and challenges within the healthcare technology sector. OPERe's "Pokesapo" service is highlighted for its successful funding round and unique approach to patient-provider communication, leveraging existing hospital materials and the LINE platform to streamline information sharing. The text also discusses HELTEC's new fall risk assessment feature for its walking analysis device, emphasizing its diagnostic capabilities. Furthermore, it addresses the abrupt termination of the partnership between Novo Nordisk and Hims & Hers, detailing concerns over deceptive marketing and the sale of unapproved GLP-1 medications. Finally, the collection introduces Beijing University's groundbreaking "NanoFLUID" electronic bandage, which promises more efficient drug delivery to internal organs through electrical charges.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

OPERE, operator of medical communication SaaS “Pokesapo,” raises 400 million yen in pre-Series A funding. How does it differ from patient explanation support services such as Contrea and MediOS?

OPERE, operator of medical communication SaaS “Pokesapo,” raises 400 million yen in pre-Series A funding. How does it differ from patient explanation support services such as Contrea and MediOS?

Kazutaka Yoshinaga